ATP5B Is Involved In The Formation Of Hepatic Cavernous Hemangioma

Background/Aim：Hepatic cavernous hemangioma (HCH) is the most commonbenign tumor in liver, but the pathogenesis is largely unknown. Aberrantlyexpressed proteins in HCH were investigated in this article to explore HCHdevelopment.Methods：Aberrantly expressed proteins in human hepatic cavernous hemangiomacompared with normal hepatic tissue were identified with2-dimensionalelectrophoresis (2-DE), matrix-assisted laser desorption/ionization times offlight mass spectrometry (MALDI-TOF-MS) and peptide massfingerprinting (PMF). Then, aberrantly expressed proteins in HCH wereverified with western blot (WB) and immunohistochemistry (IMC). Finally,the role of identified protein in angiogenesis was evaluated with chickenchorio-allantoic membrane (CAM) assay.Results:1,9proteins were found to be aberrantly expressed in human HCH comparedto normal livers, including3over-expressed,2lower expressed and4only expressed in normal liver but not in HCH.2, Among those proteins,mitochondrial ATP synthase, H+transporting F1complex beta subunit(ATP5B) was selected for further investigation. ATP5B was found to bemainly expressed in endothelial cells in HCH but not in normal liver andpromoted angiogenesis on CAM model.Conclusions: Our studies found that several aberrantly expressed proteins may beinvolved in HCH pathogenesis. Among which, ATP5B plays an importantrole in formation of hepatic cavernous hemangioma through angiogenesispromotion, ATP5B may be a molecular target in hepatic cavernoushemangioma therapy and prevention.